Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

Please provide your email address to receive an email when new articles are posted on . In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to ...

Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia (CML) patients who do not respond well to tyrosine ...

When you talk to your doctor about treatment for chronic myelogenous leukemia (CML), you may hear him say that your goal is to get into remission. If you're like most folks, you've got a general idea ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...